Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Skye Bioscience Inc (SKYE)

Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,775
  • Shares Outstanding, K 32,057
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,570 K
  • EBIT $ -54 M
  • EBITDA $ -53 M
  • 60-Month Beta 2.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.95

Options Overview Details

View History
  • Implied Volatility 251.23% (-5.36%)
  • Historical Volatility 105.79%
  • IV Percentile 42%
  • IV Rank 21.63%
  • IV High 806.91% on 12/05/25
  • IV Low 97.86% on 04/04/25
  • Expected Move (DTE 21) 1.6150 (159.90%)
  • Put/Call Vol Ratio 59.00
  • Today's Volume 120
  • Volume Avg (30-Day) 87
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 3,535
  • Open Int (30-Day) 3,265
  • Expected Range 0.0000 to 2.6250

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.29
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.36
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -20.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6844 +47.57%
on 12/31/25
1.1500 -12.17%
on 01/07/26
+0.2830 (+38.93%)
since 12/30/25
3-Month
0.6844 +47.57%
on 12/31/25
1.6200 -37.65%
on 10/31/25
-0.4600 (-31.29%)
since 10/30/25
52-Week
0.6844 +47.57%
on 12/31/25
5.7500 -82.43%
on 06/27/25
-2.7400 (-73.07%)
since 01/30/25

Most Recent Stories

More News
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 1.0100 (+5.21%)
Skye Bioscience to Present Poster at Keystone Obesity Conference

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

SKYE : 1.0100 (+5.21%)
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

LOS ANGELES , Jan. 19, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations...

SKYE : 1.0100 (+5.21%)
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Jan. 19, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience,...

SKYE : 1.0100 (+5.21%)
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

NEW YORK , Jan. 16, 2026 /PRNewswire/ -- 

SKYE : 1.0100 (+5.21%)
Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE).

SKYE : 1.0100 (+5.21%)
Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE

NEW YORK , Jan. 14, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in  Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities...

SKYE : 1.0100 (+5.21%)
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

LOS ANGELES , Jan. 14, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations...

SKYE : 1.0100 (+5.21%)
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Jan. 14, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye"...

SKYE : 1.0100 (+5.21%)
FRIDAY DEADLINE: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

PHILADELPHIA , Jan. 13, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE)...

SKYE : 1.0100 (+5.21%)

Business Summary

Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif.

See More

Key Turning Points

3rd Resistance Point 1.1253
2nd Resistance Point 1.0743
1st Resistance Point 1.0421
Last Price 1.0100
1st Support Level 0.9589
2nd Support Level 0.9079
3rd Support Level 0.8757

See More

52-Week High 5.7500
Fibonacci 61.8% 3.8149
Fibonacci 50% 3.2172
Fibonacci 38.2% 2.6195
Last Price 1.0100
52-Week Low 0.6844

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar